Clinical Chemistry Standards
Abcam DL-AP5, NMDA glutamate site antagonist, 50MG
MW 197.13 Da, Purity >99%. Competitive NMDA receptor glutamate site antagonist. Also available as the sodium salt (ab120271).
The product is subject to the following: Abcam Restricted Use Statement
Abcam L-AP4, group III mGlu agonist, 1MG
MW 183.1 Da, Purity >99%. Selective group III mGlu agonist. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam DL-AP5, NMDA glutamate site antagonist, 10MG
MW 197.13 Da, Purity >99%. Competitive NMDA receptor glutamate site antagonist. Also available as the sodium salt (ab120271).
The product is subject to the following: Abcam Restricted Use Statement
Abcam DL-AP4, glutamate antagonist, 1G
MW 183.1 Da, Purity >99%. Broad spectrum glutamate antagonist. Water-soluble form available - please see DL-AP4 sodium salt (ab120253).
The product is subject to the following: Abcam Restricted Use Statement
Abcam DL-AP4, glutamate antagonist, 100MG
MW 183.1 Da, Purity >99%. Broad spectrum glutamate antagonist. Water-soluble form available - please see DL-AP4 sodium salt (ab120253).
The product is subject to the following: Abcam Restricted Use Statement
![OriGene Cardiac Troponin I (TNNI3) Mouse Monoclonal Antibody [Clone ID: OTI3G2]](https://assets.fishersci.com/TFS-Assets/CCG/product-images/502543098.JPG-250.jpg)
OriGene Cardiac Troponin I (TNNI3) Mouse Monoclonal Antibody [Clone ID: OTI3G2]
Cardiac Troponin I (TNNI3) Mouse Monoclonal Antibody [Clone ID: OTI3G2]
ABclonal Technology Cardiac Troponin I TNNI3
Troponin I (TnI) along with TnT and TnC forms the troponin complex in striated muscle where TnI inhibits actin-myosin interactions mediating muscle relaxation The TnI subfamily includes TnI-skeletal-fast-twitch TnI-skeletal-slow-twitch and TnI-cardiac with this gene encoding the cardiac isoform expressed only in cardiac muscle Mutations in this gene cause familial hypertrophic cardiomyopathy type 7 (CMH7) and familial restrictive cardiomyopathy (RCM) TnI is a key diagnostic marker for heart failure ischemic heart disease and acute myocardial injury including in COVID-19 patients where elevated levels indicate increased mortality risk particularly in those with pre-existing cardiovascular conditions
ABclonal Technology Cardiac Troponin I TNNI3
Troponin I (TnI) along with TnT and TnC forms the troponin complex in striated muscle where TnI inhibits actin-myosin interactions mediating muscle relaxation The TnI subfamily includes TnI-skeletal-fast-twitch TnI-skeletal-slow-twitch and TnI-cardiac with this gene encoding the cardiac isoform expressed only in cardiac muscle Mutations in this gene cause familial hypertrophic cardiomyopathy type 7 (CMH7) and familial restrictive cardiomyopathy (RCM) TnI is a key diagnostic marker for heart failure ischemic heart disease and acute myocardial injury including in COVID-19 patients where elevated levels indicate increased mortality risk particularly in those with pre-existing cardiovascular conditions
Genscript Corporation MonoRab NT-proBNP 10B11 mA
BNP and NT-proBNP are separated from precursor molecule proBNP via proteolytic processing The BNP and NT-proBNP level in blood are proportional to the severity of cardiac dysfunction They can be used for diagnosis of congestive heart failure (CHF)
Genscript Corporation Cardiac Troponin I cTnI His
Cardiac Troponin I (cTnI) is a subtype of the troponin family that is commonly used as a marker for myocardial damage Cardiac troponin I is specific for cardiac tissue and is detected in the serum only if myocardial injury has occurred Because cardiac troponin I is a very sensitive and specific indicator of heart muscle (myocardium) damage serum levels can be used to help differentiate between unstable angina and myocardial infarction (heart attack) in people with chest pain or acute coronary syndrome
Genscript Corporation Cardiac Troponin T cTnT Anti
Cardiac Troponin T (cTnT) Antibody (4B6H2) mAb Mouse